Veradermics Incorporated (MANE)
MANE trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MANE on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001827635 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Recent IPO: no annual report filed yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In accordance with Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40) , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are is" | 10-Q 2026-11-10 |
| Cash and burn | $132.2M cash; operating cash flow -$20.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 42,195,472 (2026-11-05). | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Hartford, Connecticut, United States | PCAOB Form AP 2026-04-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $34.8M, sold $103.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$21.0M | -$22.9M | $132.2M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$23.5M | -$14.5M | $319.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$27.2M | -$21.2M | $168.4M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$21.8M | -$23.6M | $21.8M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$20.1M | -$19.0M | $5.7M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$15.6M | -$15.6M | $8.6M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$12.4M | -$13.3M | $32.4M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-14 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 104 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.6% |
| 1 month | +11.5% |
| 3 months | +16.8% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -17.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
| LQDA | Liquidia Corporation | $56.37 | -1.81% | $5.1B |
| DNTH | Dianthus Therapeutics Inc. | $89.55 | -2.46% | $5.0B |
| MIRM | Mirum Pharmaceuticals Inc. | $91.58 | -2.56% | $6.0B |
| SUPN | Supernus Inc. | $28.83 | -2.99% | $6.0B |
| GRFS | Grifols S.A. | $8.73 | +0.46% | $6.0B |
| LGND | Ligand Pharmaceuticals Incorporated | $301.71 | -2.29% | $6.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier